These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35800545)

  • 21. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Vaccine Hesitancy: The Perils of Peddling Science by Social Media and the Lay Press.
    Thorakkattil SA; Abdulsalim S; Karattuthodi MS; Unnikrishnan MK; Rashid M; Thunga G
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    Hills SL; Soeung SC; Sarath S; Morn C; Dara C; Fischer M; Thigpen MC
    PLoS One; 2022; 17(6):e0269480. PubMed ID: 35679297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptance and adverse effects following COVID-19 vaccination among the health care workers at a health care centre in the most backward district of India.
    Sharma A; Jain M; Vigarniya M
    J Family Med Prim Care; 2022 Jun; 11(6):3224-3229. PubMed ID: 36119236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala.
    Jose M; Rajmohan P; Thomas J; Krishna S; Antony B; Gopinathan UU; Iyyapan EM; Porinchu RM; Jose P; Raphael L; Kuttichira P
    Curr Drug Saf; 2022; 17(4):327-334. PubMed ID: 35135453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.
    Spinelli FR; Favalli EG; Garufi C; Cornalba M; Colafrancesco S; Conti F; Caporali R
    Arthritis Res Ther; 2022 Jan; 24(1):21. PubMed ID: 35016701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study.
    Zeitoun A; Hallit S; Chehade S; Ibrahim A; Helali M; Allam C; Karam R
    J Pharm Policy Pract; 2023 Feb; 16(1):24. PubMed ID: 36810279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cross-sectional Survey of Public Knowledge and Perspective on Coronavirus Disease, Vaccination, and Related Research in India during the COVID-19 Pandemic.
    Munshi R; Maurya M
    J Assoc Physicians India; 2023 Sep; 71(9):19-27. PubMed ID: 38700297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine Safety: Assessing the Prevalence and Severity of Adverse Events Following COVID-19 Vaccination amongst Healthcare Workers in Tertiary Health Facilities in Nigeria.
    Azees AS; Fasiku MM; Isa A; Ezenwoko AZ; Ahmed A; Temitayo-Oboh AO; Utulu R; Adeniyi MA; Musa A; Alo C; Ibrahim UM; Imhonopi GB; Adesoye OO; Okeke IM; John GT; Ayinla AY
    Niger Postgrad Med J; 2024 Jan; 31(1):1-7. PubMed ID: 38321791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines.
    Jhaj R; Chaudhary D; Shukla AK; Yadav J
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study.
    Velhal GD; Kamath YV; Agrawal AS; Vora DS; Dwivedi VR
    Indian J Community Med; 2022; 47(4):613-617. PubMed ID: 36742958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel.
    Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Widhani A; Aini MH; Rahmadani M; Istanti ND; Giantini A
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: An observational analytical study.
    Shukla V; Sachan B; Jauhari S; Bhardwaj S; Pathak A; Kandpal SD
    J Family Med Prim Care; 2023 Mar; 12(3):460-465. PubMed ID: 37122665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccination hesitance and adverse effects among US adults: a longitudinal cohort study.
    Abdelmasseh M; Cuaranta A; Iqbal A; Kadiyala V; Willis J; Gorka A; Thompson E; Finley R; Payne B; Sanabria J
    Front Epidemiol; 2024; 4():1365090. PubMed ID: 39081839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021.
    Ehde DM; Roberts MK; Humbert AT; Herring TE; Alschuler KN
    Mult Scler Relat Disord; 2021 Sep; 54():103163. PubMed ID: 34325399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand.
    Mahasing C; Doungngern P; Jaipong R; Nonmuti P; Chimmanee J; Wongsawat J; Boonyasirinant T; Wanlapakorn C; Leelapatana P; Yingchoncharoen T; Ngarmukos T; Chokephaibulkit K; Srimahachota S
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.